Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shiga toxin 2e (Stx2e) is a subtype of Shiga toxin 2 produced by certain Escherichia coli strains, belonging to the AB5 family of bacterial protein toxins with molecular weight around 70 kDa.[1][3] It consists of an enzymatic A subunit that cleaves an adenine residue from the 28S rRNA of the 60S ribosome, halting protein synthesis in eukaryotic target cells, and a pentameric B subunit that binds preferentially to globotetraosylceramide (Gb4) rather than the typical globotriaosylceramide (Gb3).[1][3] Unlike more human-pathogenic subtypes like Stx2a, Stx2e is primarily associated with porcine edema disease, a severe neurological disorder in pigs characterized by edema and high fatality rates, with prototype strain S1191.[1][3] The toxin is encoded in a lambda-like bacteriophage operon and exhibits differences in receptor binding and cytotoxicity compared to other Stx2 variants.[1][3] No approved therapeutic drugs directly target Stx2e, as it is a virulence factor rather than a host therapeutic target, and efforts focus on preventing E. coli infections or neutralizing Stx broadly in veterinary contexts.[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shiga toxin 2e (Stx2e).